KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Non-Current Deffered Revenue (2019 - 2025)

Aquestive Therapeutics (AQST) has 7 years of Non-Current Deffered Revenue data on record, last reported at $19.4 million in Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 3.07% year-over-year to $19.4 million; the TTM value through Dec 2025 reached $19.4 million, down 3.07%, while the annual FY2025 figure was $19.4 million, 3.07% down from the prior year.
  • Non-Current Deffered Revenue reached $19.4 million in Q4 2025 per AQST's latest filing, down from $19.7 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $33.1 million in Q2 2023 and bottomed at $4.7 million in Q1 2021.
  • Average Non-Current Deffered Revenue over 5 years is $20.3 million, with a median of $19.8 million recorded in 2025.
  • Peak YoY movement for Non-Current Deffered Revenue: skyrocketed 341.13% in 2022, then plummeted 38.22% in 2025.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $7.1 million in 2021, then surged by 341.13% to $31.4 million in 2022, then grew by 2.95% to $32.3 million in 2023, then plummeted by 38.15% to $20.0 million in 2024, then fell by 3.07% to $19.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $19.4 million in Q4 2025, $19.7 million in Q3 2025, and $19.9 million in Q2 2025.